BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020;92S:S15-25. [PMID: 32032752 DOI: 10.1016/j.ijid.2020.01.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Kozińska M, Bogucka K, Kędziora K, Szpak-szpakowska J, Pędzierska-olizarowicz W, Pustkowski A, Augustynowicz-kopeć E. XDR-TB Transmitted from Mother to 10-Month-Old Infant: Diagnostic and Therapeutic Problems. Diagnostics 2022;12:438. [DOI: 10.3390/diagnostics12020438] [Reference Citation Analysis]
2 Migliori GB, Visca D, van den Boom M, Tiberi S, Silva DR, Centis R, D'Ambrosio L, Thomas T, Pontali E, Saderi L, Schaaf HS, Sotgiu G; contributing members of the Global Tuberculosis Network. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology 2021;27:248-56. [PMID: 33547028 DOI: 10.1016/j.pulmoe.2020.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Babar ZU, Nasim A, Kumar S, Nazmi J, Badlani S, Nadeem A, Aziz T. A case series of multidrug-resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country. Transpl Infect Dis 2021;:e13659. [PMID: 34057810 DOI: 10.1111/tid.13659] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Dahl V, Migliori GB, Lange C, Wejse C. War in Ukraine: an immense threat to the fight against tuberculosis. Eur Respir J 2022;59:2200493. [PMID: 35450921 DOI: 10.1183/13993003.00493-2022] [Reference Citation Analysis]
5 Nguyen TVA, Anthony RM, Cao TTH, Bañuls AL, Nguyen VAT, Vu DH, Nguyen NV, Alffenaar JC. Delamanid Resistance: Update and Clinical Management. Clin Infect Dis 2020;71:3252-9. [PMID: 32521000 DOI: 10.1093/cid/ciaa755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Charlie L, Saidi B, Getachew E, Wanjiru CL, Abebe M, Tesfahunei HA, Atim MG, Manyazewal T, Mlera RN. Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi. Int J Mycobacteriol 2021;10:255-9. [PMID: 34494563 DOI: 10.4103/ijmy.ijmy_47_21] [Reference Citation Analysis]
7 Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, Allwood B, Byrne AL, Mortimer K, Wallis RS, Fox GJ, Leung CC, Chakaya JM, Seaworth B, Rachow A, Marais BJ, Furin J, Akkerman OW, Al Yaquobi F, Amaral AFS, Borisov S, Caminero JA, Carvalho ACC, Chesov D, Codecasa LR, Teixeira RC, Dalcolmo MP, Datta S, Dinh-Xuan AT, Duarte R, Evans CA, García-García JM, Günther G, Hoddinott G, Huddart S, Ivanova O, Laniado-Laborín R, Manga S, Manika K, Mariandyshev A, Mello FCQ, Mpagama SG, Muñoz-Torrico M, Nahid P, Ong CWM, Palmero DJ, Piubello A, Pontali E, Silva DR, Singla R, Spanevello A, Tiberi S, Udwadia ZF, Vitacca M, Centis R, D Ambrosio L, Sotgiu G, Lange C, Visca D. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021;25:797-813. [PMID: 34615577 DOI: 10.5588/ijtld.21.0425] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Riskiyev A, Ciobanu A, Hovhannesyan A, Akopyan K, Gadoev J, Parpieva N. Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan. Int J Environ Res Public Health 2021;18:6541. [PMID: 34204519 DOI: 10.3390/ijerph18126541] [Reference Citation Analysis]
9 Malwal SR, Zimmerman MD, Alvarez N, Sarathy JP, Dartois V, Nacy CA, Oldfield E. Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate. ACS Infect Dis 2021;7:2492-507. [PMID: 34279904 DOI: 10.1021/acsinfecdis.1c00259] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Tiberi S, Utjesanovic N, Galvin J, Centis R, D'Ambrosio L, van den Boom M, Zumla A, Migliori GB. Drug resistant TB - latest developments in epidemiology, diagnostics and management. Int J Infect Dis 2022:S1201-9712(22)00165-5. [PMID: 35342000 DOI: 10.1016/j.ijid.2022.03.026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Campomizzi CS, Ghanatios GE, Estrada DF. 19F-NMR reveals substrate specificity of CYP121A1 in Mycobacterium tuberculosis. J Biol Chem 2021;297:101287. [PMID: 34634307 DOI: 10.1016/j.jbc.2021.101287] [Reference Citation Analysis]
12 Nuwagira E, Yekosani M, Abraham B, Atwine R, Caleb T, Baluku JB. Drug-Resistant Tuberculosis Presenting as a Testicular Mass: A Case Report. Int Med Case Rep J 2021;14:145-9. [PMID: 33688269 DOI: 10.2147/IMCRJ.S300216] [Reference Citation Analysis]
13 Wang P, Batt SM, Wang B, Fu L, Qin R, Lu Y, Li G, Besra GS, Huang H. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. J Med Chem 2021;64:6241-61. [PMID: 33852302 DOI: 10.1021/acs.jmedchem.1c00263] [Reference Citation Analysis]
14 Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, Dalcolmo M, Shakya SR, Miliauskas S, Kuksa L, Manga S, Aleksa A, Denholm JT, Khadka HB, Skrahina A, Diktanas S, Ferrarese M, Bruchfeld J, Koleva A, Piubello A, Koirala GS, Udwadia ZF, Palmero DJ, Munoz-Torrico M, Gc R, Gualano G, Grecu VI, Motta I, Papavasileiou A, Li Y, Hoefsloot W, Kunst H, Mazza-Stalder J, Payen MC, Akkerman OW, Bernal E, Manfrin V, Matteelli A, Mustafa Hamdan H, Nieto Marcos M, Cadiñanos Loidi J, Cebrian Gallardo JJ, Duarte R, Escobar Salinas N, Gomez Rosso R, Laniado-Laborín R, Martínez Robles E, Quirós Fernandez S, Rendon A, Solovic I, Tadolini M, Viggiani P, Belilovski E, Boeree MJ, Cai Q, Davidavičienė E, Forsman LD, De Los Rios J, Drakšienė J, Duga A, Elamin SE, Filippov A, Garcia A, Gaudiesiute I, Gavazova B, Gayoso R, Gruslys V, Jonsson J, Khimova E, Madonsela G, Magis-Escurra C, Marchese V, Matei M, Moschos C, Nakčerienė B, Nicod L, Palmieri F, Pontarelli A, Šmite A, Souleymane MB, Vescovo M, Zablockis R, Zhurkin D, Alffenaar JW, Caminero JA, Codecasa LR, García-García JM, Esposito S, Saderi L, Spanevello A, Visca D, Tiberi S, Pontali E, Centis R, D'Ambrosio L, van den Boom M, Sotgiu G, Migliori GB. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology 2021;27:403-12. [PMID: 33753021 DOI: 10.1016/j.pulmoe.2021.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Fekadu G, Chow DY, You JHS. The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art. Expert Opin Pharmacother 2021;:1-10. [PMID: 34402698 DOI: 10.1080/14656566.2021.1967930] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Keikha M, Karbalaei M. High resolution melting assay as a reliable method for diagnosing drug-resistant TB cases: a systematic review and meta-analysis. BMC Infect Dis 2021;21:989. [PMID: 34551717 DOI: 10.1186/s12879-021-06708-1] [Reference Citation Analysis]
17 Diel R, Sotgiu G, Andres S, Hillemann D, Maurer FP. Cost of multidrug resistant tuberculosis in Germany-An update. Int J Infect Dis 2021;103:102-9. [PMID: 33157286 DOI: 10.1016/j.ijid.2020.10.084] [Reference Citation Analysis]
18 Bahraminia F, Azimi T, Zangiabadian M, Nasiri MJ, Goudarzi M, Dadashi M, Imani Fooladi AA. Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis. Iran J Basic Med Sci 2021;24:720-5. [PMID: 34630948 DOI: 10.22038/ijbms.2021.47360.10901] [Reference Citation Analysis]
19 Chang V, Ling RH, Velen K, Fox GJ. Latent tuberculosis infection among contacts of patients with multidrug-resistant tuberculosis in New South Wales, Australia. ERJ Open Res 2021;7:00149-2021. [PMID: 34549043 DOI: 10.1183/23120541.00149-2021] [Reference Citation Analysis]
20 Sinitsyn MV, Kalinina MV, Belilovskiy EM, Galstyan AS, Reshetnikov MN, Plotkin DV. [The treatment of tuberculosis under current conditions]. Ter Arkh 2020;92:86-94. [PMID: 33346467 DOI: 10.26442/00403660.2020.08.000762] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Oliveira O, Gaio R, Correia-Neves M, Rito T, Duarte R. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016. PLoS One 2021;16:e0250028. [PMID: 33878119 DOI: 10.1371/journal.pone.0250028] [Reference Citation Analysis]
22 Bouzeyen R, Javid B. Therapeutic Vaccines for Tuberculosis: An Overview. Front Immunol 2022;13:878471. [DOI: 10.3389/fimmu.2022.878471] [Reference Citation Analysis]
23 Li P, Wang B, Fu L, Guo K, Ma C, Wang B, Lin Z, Li G, Huang H, Lu Y. Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis. Eur J Med Chem 2021;222:113603. [PMID: 34126456 DOI: 10.1016/j.ejmech.2021.113603] [Reference Citation Analysis]
24 Abrahams KA, Besra GS. Mycobacterial drug discovery. RSC Med Chem 2020;11:1354-65. [PMID: 34085044 DOI: 10.1039/d0md00261e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Basarab GS, Ghorpade S, Gibhard L, Mueller R, Njoroge M, Peton N, Govender P, Massoudi LM, Robertson GT, Lenaerts AJ, Boshoff HI, Joerss D, Parish T, Durand-Reville TF, Perros M, Singh V, Chibale K. Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones. Antimicrob Agents Chemother 2022;:e0219221. [PMID: 35266826 DOI: 10.1128/aac.02192-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tiberi S, Migliori GB, Muhwa Chakaya J, Kaesava T, Al Abri SS, Wejse C, Goletti D, Kapata N, Sotgiu G, Bomanji J, Zellweger JP, Hasan R, Irfan M, Ahmed I, Pshenichnaya N, Vasilieva I, Yeboah-Manu D, Alffenaar JW, Kim HY, Centis R, Cirillo DM, Alagna R, D'Ambrosio L, Cui X, Cao B, Maeurer M, Harries AD, Ippolito G, Raviglione M, Zumla A, Petersen E. Commemorating World TB Day 2020: "IT'S TIME" - It's time to End the Global TB Epidemic. Int J Infect Dis 2020;92S:S1-4. [PMID: 32145464 DOI: 10.1016/j.ijid.2020.03.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Oelofse S, Esmail A, Diacon AH, Conradie F, Olayanju O, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Wills GH, Olugbosi M, Del Parigi A, Sun E, Calatroni A, Spigelman M, Dheda K. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts. Int J Tuberc Lung Dis 2021;25:453-60. [PMID: 34049607 DOI: 10.5588/ijtld.21.0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, Tiberi S, Adlhoch C, Alonzi T, Archuleta S, Brusin S, Cambau E, Capobianchi MR, Castilletti C, Centis R, Cirillo DM, D'Ambrosio L, Delogu G, Esposito SMR, Figueroa J, Friedland JS, Ho BCH, Ippolito G, Jankovic M, Kim HY, Rosales Klintz S, Ködmön C, Lalle E, Leo YS, Leung CC, Märtson AG, Melazzini MG, Najafi Fard S, Penttinen P, Petrone L, Petruccioli E, Pontali E, Saderi L, Santin M, Spanevello A, van Crevel R, van der Werf MJ, Visca D, Viveiros M, Zellweger JP, Zumla A, Goletti D. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J 2020;56:2001727. [PMID: 32586885 DOI: 10.1183/13993003.01727-2020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
29 Kabir S, Junaid K, Rehman A. Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis. Int J Infect Dis 2021;103:56-61. [PMID: 33181327 DOI: 10.1016/j.ijid.2020.11.007] [Reference Citation Analysis]
30 Migliori GB, Luna JC, Kurhasani X, Boom MVD, Visca D, D'ambrosio L, Centis R, Tiberi S. History of prevention, diagnosis, treatment and rehabilitation of pulmonary sequelae of tuberculosis. La Presse Médicale 2022. [DOI: 10.1016/j.lpm.2022.104112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Mwaba P, Chakaya JM, Petersen E, Wejse C, Zumla A, Kapata N. Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis - End of the road? Int J Infect Dis 2020;92S:S69-71. [PMID: 32119979 DOI: 10.1016/j.ijid.2020.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
32 D'Ambrosio L, Centis R, Dobler CC, Tiberi S, Matteelli A, Denholm J, Zenner D, Al-Abri S, Alyaquobi F, Arbex MA, Belilovskiy E, Blanc FX, Borisov S, Carvalho ACC, Chakaya JM, Cocco N, Codecasa LR, Dalcolmo MP, Dheda K, Dinh-Xuan AT, Esposito SR, García-García JM, Li Y, Manga S, Marchese V, Muñoz Torrico M, Pontali E, Rendon A, Rossato Silva D, Singla R, Solovic I, Sotgiu G, van den Boom M, Nhung NV, Zellweger JP, Migliori GB. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics (Basel) 2021;10:1355. [PMID: 34827293 DOI: 10.3390/antibiotics10111355] [Reference Citation Analysis]
33 Fekadu G, To KKW, You JHS. WITHDRAWN: Pretomanid for the treatment of Mycobacterium tuberculosis: Evidence on the development and clinical roles. J Infect Public Health 2021:S1876-0341(21)00324-5. [PMID: 34742640 DOI: 10.1016/j.jiph.2021.09.030] [Reference Citation Analysis]
34 Lucey O, Potter J, Ricketts W, Castle L, Melzer M. Utility of EBUS-TBNA in diagnosing mediastinal tuberculous lymphadenitis in East London. J Infect 2021:S0163-4453(21)00531-4. [PMID: 34706281 DOI: 10.1016/j.jinf.2021.10.015] [Reference Citation Analysis]
35 Migliori GB, Tiberi S, García-Basteiro AL, Duarte R. Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. Pulmonology 2021;27:94-6. [PMID: 33272908 DOI: 10.1016/j.pulmoe.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Gill CM, Dolan L, Piggott LM, Mclaughlin AM. New developments in tuberculosis diagnosis and treatment. Breathe 2022;18:210149. [DOI: 10.1183/20734735.0149-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, Aquaro S, Rosano C, Sinicropi MS. Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies. Molecules 2022;27:616. [PMID: 35163878 DOI: 10.3390/molecules27030616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
38 Tiresse N, Oucharqui S, Benaissa E, Badri B, Bssaibis F, Maleb A, Elouennass M. The occurrence of a multidrug-resistant tuberculous retropharyngeal abscess in an immunocompetent patient: A case report. IDCases 2021;26:e01282. [PMID: 34527513 DOI: 10.1016/j.idcr.2021.e01282] [Reference Citation Analysis]
39 Ramachandran G, Rajivgandhi GN, Chackaravarthi G, Kanisha CC, Siddiqi MZ, Alharbi NS, Kadaikunnan S, Manoharan N. Isolation and molecular identification of extended spectrum beta-lactamase producing bacteria from urinary tract infection. J Infect Public Health 2021;14:1911-6. [PMID: 34785167 DOI: 10.1016/j.jiph.2021.10.016] [Reference Citation Analysis]
40 Singh V, Chibale K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Acc Chem Res 2021;54:2361-76. [PMID: 33886255 DOI: 10.1021/acs.accounts.0c00878] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
41 Gupta R, Al-Kharji NMSA, Alqurafi MA, Nguyen TQ, Chai W, Quan P, Malhotra R, Simcox BS, Mortimer P, Brammer Basta LA, Rohde KH, Buynak JD. Atypically Modified Carbapenem Antibiotics Display Improved Antimycobacterial Activity in the Absence of β-Lactamase Inhibitors. ACS Infect Dis 2021;7:2425-36. [PMID: 34191496 DOI: 10.1021/acsinfecdis.1c00185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Song Q, Guo X, Zhang L, Yang L, Lu X. New Approaches in the Classification and Prognosis of Sign Clusters on Pulmonary CT Images in Patients With Multidrug-Resistant Tuberculosis. Front Microbiol 2021;12:714617. [PMID: 34671326 DOI: 10.3389/fmicb.2021.714617] [Reference Citation Analysis]
43 Gureva T, Turkova A, Yablokova E, Smirnova P, Sveshnikova O, Zolotaya O, Nikishova E, Heldal E, Hinderaker S, Seddon JA, Mariandyshev A. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int J Tuberc Lung Dis 2022;26:171-3. [PMID: 35086631 DOI: 10.5588/ijtld.21.0443] [Reference Citation Analysis]
44 Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, D'Ambrosio L, Denholm JT, Schaaf HS, van den Boom M, Kurhasani X, Dalcolmo MP, Al-Abri S, Chakaya J, Alffenaar JW, Akkerman O, Silva DR, Muňoz-Torrico M, Seaworth B, Pontali E, Saderi L, Tiberi S, Zumla A, Migliori GB, Sotgiu G. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis 2022:S1201-9712(22)00125-4. [PMID: 35245659 DOI: 10.1016/j.ijid.2022.02.043] [Reference Citation Analysis]
45 Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis 2021:S1201-9712(21)00153-3. [PMID: 33713815 DOI: 10.1016/j.ijid.2021.02.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Prajapati JD, Kleinekathöfer U, Winterhalter M. How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics. Chem Rev 2021;121:5158-92. [PMID: 33724823 DOI: 10.1021/acs.chemrev.0c01213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
47 Gadicherla S, Krishnappa L, Madhuri B, Mitra SG, Ramaprasad A, Seevan R, Sreeganga SD, Thodika NK, Mathew S, Suresh V. Envisioning a learning surveillance system for tuberculosis. PLoS One 2020;15:e0243610. [PMID: 33315902 DOI: 10.1371/journal.pone.0243610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
48 Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond) 2020;52:902-7. [PMID: 32808838 DOI: 10.1080/23744235.2020.1806353] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
49 Liu P, Fan S, Wang B, Cao R, Wang X, Li S, Lu Y, Zhong W. Design, synthesis and biological evaluation of novel triaryldimethylaminobutan-2-ol derivatives against Mycobacterium tuberculosis. Bioorg Chem 2020;102:104054. [PMID: 32663665 DOI: 10.1016/j.bioorg.2020.104054] [Reference Citation Analysis]
50 Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, Dhama K, Ripon MKH, Gajdács M, Sahibzada MUK, Hossain MJ, Koirala N. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. J Infect Public Health 2021:S1876-0341(21)00340-3. [PMID: 34756812 DOI: 10.1016/j.jiph.2021.10.020] [Reference Citation Analysis]
51 Visca D, Tiberi S, Centis R, D’ambrosio L, Pontali E, Mariani AW, Zampogna E, van den Boom M, Spanevello A, Migliori GB. Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation. Applied Sciences 2020;10:2734. [DOI: 10.3390/app10082734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]